Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Long-Term Deferred Tax (2019 - 2022)

Madrigal Pharmaceuticals (MDGL) has disclosed Long-Term Deferred Tax for 3 consecutive years, with $117000.0 as the latest value for Q4 2023.

  • On a quarterly basis, Long-Term Deferred Tax changed N/A to $117000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $117000.0, a N/A change, with the full-year FY2023 number at $117000.0, changed N/A from a year prior.
  • Long-Term Deferred Tax was $117000.0 for Q4 2023 at Madrigal Pharmaceuticals, up from $14000.0 in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $117000.0 in Q4 2023 to a low of $14000.0 in Q4 2020.
  • A 3-year average of $64333.3 and a median of $62000.0 in 2019 define the central range for Long-Term Deferred Tax.
  • Biggest YoY gain for Long-Term Deferred Tax was 77.42% in 2020; the steepest drop was 77.42% in 2020.
  • Madrigal Pharmaceuticals' Long-Term Deferred Tax stood at $62000.0 in 2019, then crashed by 77.42% to $14000.0 in 2020, then surged by 735.71% to $117000.0 in 2023.
  • Per Business Quant, the three most recent readings for MDGL's Long-Term Deferred Tax are $117000.0 (Q4 2023), $14000.0 (Q4 2020), and $62000.0 (Q4 2019).